Company: RGNX
Filing Date: 2025-03-13
Form Type: 10-K
Source: 0000950170-25-038770
Chunk: 12

Company: REGENXBIO Inc.
Filing Date: 2025-03-13
Form: 10-K
Item: Item 16
Chunk 12
---
 —

    —

    1,512

    Issuance of common stock under employee    stock purchase plan

    105

    —

    1,191

    —

    —

    1,191

    Issuance of common stock and pre-funded warrants   upon public offering, net of transaction   costs of $534

    4,565

    1

    131,066

    —

    —

    131,067

    Exercise of pre-funded warrants

    197

    —

    —

    —

    —

    —

    Stock-based compensation expense

    —

    —

    38,463

    —

    —

    38,463

    Unrealized gain on available-for-sale securities, net

    —

    —

    —

    3,688

    —

    3,688

    Net loss

    —

    —

    —

    —

    (227,102
    )

    (227,102
    )

    Balances at December 31, 2024

    49,549

    $
    5

    $
    1,192,536

    $
    (741
    )
     
    $
    (932,149
    )
     
    $
    259,651

The accompanying notes are an integral part of these consolidated financial statements.

92

REGENXBIO INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

    Years Ended December 31,

    2024

    2023

    2022

    Cash flows from operating activities

    Net loss
     
    $
    (227,102
    )
     
    $
    (263,494
    )
     
    $
    (280,321
    )

    Adjustments to reconcile net loss to net cash used in operating activities

    Stock-based compensation expense

    38,463

    40,267

    40,788

    Depreciation and amortization

    16,215

    17,320

    12,909

    Provision for credit losses (recoveries)

    (5,000
    )

    —

    —

    Net amortization of premiums (accretion of discounts) on marketable debt securities

    (4,144
    )

    687

    4,712

    Net realized loss (gain) on investments

    (6